News Stories

Newly Defined Term Lipid Specialist Aims to Formalize Medical Specialty, Enhance Public Understanding of Blood Fat Disorders and Optimal Treatment

JACKSONVILLE, Fla. – (May 17, 2019) -- The National Lipid Association (NLA) today announced the release of an official scientific statement on Lipoprotein(a) [Lp(a)] clinical use at the NLA 2019 Scientific Sessions, May 16 – 19 at the Turnberry Isle Miami in Aventura, Florida.

Created by an international team of clinical lipid experts (see list on page 2), the statement is designed as a comprehensive source of guidance for medical professionals making decisions to improve the health and well-being of children and adults at risk of premature cardiovascular disease.

Regeneron Pharmaceuticals, Inc. and Sanofi have announced that the U.S. Food and Drug Administraion (FDA) has approved Praluent®  (alirocumab) to reduce the risk of heart attack, stroke and unstable angina requiring hospitalization in adults with established cardiovascular (CV) disease.